ArticleJournal for immunotherapy of cancer2019

CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma.

Bryan D Choi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.